NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Tofacitinib (Xeljanz) Special Investigation for Rheumatoid Arthritis

NCT01932372

CompletedN/A

Sponsor: Pfizer

Conditions: Rheumatoid Arthritis

Interventions: Tofacitinib (Xeljanz), Etanercept, other Biologics, Disease-modifying antirheumatic drugs (DMARDs), etc

Countries: Japan

The objective of this Surveillance is to verify the following subject matters concerning Tofacitinib (Xeljanz) under general practice. 1\) Occurrence of adverse reactions, factors that may potentially affect safety and efficacy 2） Long-term safety (particularly, malignant tumors and serious infections) and efficacy Occurrences of malignant tumors and serious infections will be compared with a control group.

Eligibility overview

Sex: ALL

Age: 0 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* All patients receiving Tofacitinib (Xeljanz)

Exclusion Criteria:

Not Applicable

Locations (1)

Tokyo, Japan